Alzheimer's disease

Alzheimer's Association Launches New Training and Certification Program to Enhance Dementia Care

Retrieved on: 
Wednesday, March 24, 2021
Alzheimer's disease, Dementia, Psychiatric diagnosis, Human behavior, Psychiatry, Caregiver, Caring for people with dementia, Abnormal psychology, The Society for the Arts in Dementia Care, Arts & Minds

The purchase of the Person-Centered Dementia Care Training Program includes access to essentiALZ, an individual certification exam developed based on the practices put forth in the Dementia Care Practice Recommendations that demonstrate knowledge of quality care dementia practices.

Key Points: 
  • The purchase of the Person-Centered Dementia Care Training Program includes access to essentiALZ, an individual certification exam developed based on the practices put forth in the Dementia Care Practice Recommendations that demonstrate knowledge of quality care dementia practices.
  • With successful completion of the training program, care professionals are eligible to take the exam.
  • Individuals who pass the exam are certified in essentiALZ for two years, demonstrating their commitment and knowledge of providing personalized, person-centered, quality dementia care.
  • High-quality dementia care training can lead to an improvement in communication between caregivers and individuals living with dementia, a reduction in dementia-related behaviors and an increase in job satisfaction and staff retention.

Athira Pharma to Present at Stifel’s 3rd Annual CNS Conference

Retrieved on: 
Wednesday, March 24, 2021
Branches of biology, Biology, Psychiatric diagnosis, Neuroscience, Cognitive disorders, Dementia, Abnormal psychology, Alzheimer's disease, Parkinson's disease, Neurodegeneration

A live webcast of the fireside chat will also be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations .

Key Points: 
  • A live webcast of the fireside chat will also be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations .
  • Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.
  • We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action.
  • Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimers and Parkinsons dementia.

AlzeCure Pharma (ALZCUR): Initiation - Well-balanced pipeline for Alzheimer's and pain

Retrieved on: 
Wednesday, March 24, 2021
Branches of biology, Nervous system, Neuroscience, Nociception, Pain, Neuropathic pain, Alzheimer's disease, Peripheral neuropathy, Opioid

The pipeline consists of three small-molecule platforms targeting Alzheimer's disease (AD) and pain.

Key Points: 
  • The pipeline consists of three small-molecule platforms targeting Alzheimer's disease (AD) and pain.
  • The Alzstatin platform (preclinical) is specifically aimed at modifying the course of AD and has a differentiated mechanism of action.
  • The third Painless platform, with two non-opioid assets for pain (lead ACD440 is in Phase Ib), complements the R&D pipeline well.
  • Our valuation includes the two clinical stage assets, ACD856 for symptomatic treatment of AD and ACD440 for neuropathic pain.

Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference

Retrieved on: 
Tuesday, March 23, 2021
Branches of biology, Neuroscience, Biology, Psychiatric diagnosis, Dementia, Medication, Pharmaceutical industry, Alzheimer's disease, Acetylcholinesterase inhibitor, Cholinesterase inhibitor

Detroit, Michigan--(Newsfile Corp. - March 23, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company focused on neurological disorders, with near term commercialization potential for its Alpha-1062 Alzheimer's drug announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM ET.

Key Points: 
  • Detroit, Michigan--(Newsfile Corp. - March 23, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company focused on neurological disorders, with near term commercialization potential for its Alpha-1062 Alzheimer's drug announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM ET.
  • Alpha-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials.
  • It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration.
  • Its use for the treatment neurodegenerative diseases has been patented by ACI and granted an Orphan Drug Designation.

Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference

Retrieved on: 
Monday, March 22, 2021
Branches of biology, Neuroscience, Biology, Granulin, Alzheimer's disease, Neurotrophic factors

Detroit, Michigan--(Newsfile Corp. - March 22, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company with near term commercialization potential for its lead drug candidate ALPHA-1062, announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM EST.

Key Points: 
  • Detroit, Michigan--(Newsfile Corp. - March 22, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company with near term commercialization potential for its lead drug candidate ALPHA-1062, announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM EST.
  • The presentation will cover key areas of ACI's business and the ALPHA-1062 development plan for the treatment of Alzheimer's dementia.
  • ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials.
  • ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of ALS.

Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference

Retrieved on: 
Wednesday, March 17, 2021
Branches of biology, Biology, Neuroscience, Neurodegeneration, Senescence, Alzheimer's disease

Detroit, Michigan--(Newsfile Corp. - March 17, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company with near term commercialization potential for its lead drug candidate ALPHA-1062, announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM EST.

Key Points: 
  • Detroit, Michigan--(Newsfile Corp. - March 17, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company with near term commercialization potential for its lead drug candidate ALPHA-1062, announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM EST.
  • The presentation will cover key areas of ACI's business and the ALPHA-1062 development plan for the treatment of Alzheimer's dementia.
  • We invite our shareholders, and all interested parties to register for our presentation at the spectator link for the event: https://www.benzinga.com/events/small-cap/biotech/ .
  • Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis.

Cognito Therapeutics to Advance Digital Therapeutic for Alzheimer’s into Pivotal Studies Based on Positive Clinical Results Announced at AD/PD 2021

Retrieved on: 
Wednesday, March 17, 2021
Research, General Health, Radiology, Pharmaceutical, Mental health, Medical devices, Genetics, Clinical trials, Science, Biotechnology, FDA, Health, Other Science, Health sciences, Life sciences, Branches of biology, Psychiatric diagnosis, Drug discovery, Health policy, Medicinal chemistry, Therapy, Alzheimer's disease

Results from FLICKER, a 10-patient Phase 2 study, assessed the safety and tolerability of the digital therapeutic in patients with mild cognitive impairment due to AD.

Key Points: 
  • Results from FLICKER, a 10-patient Phase 2 study, assessed the safety and tolerability of the digital therapeutic in patients with mild cognitive impairment due to AD.
  • The sham group did not receive therapy for four weeks, followed by gamma neuromodulation therapy, one-hour daily for four weeks.
  • Results showed the therapy was safe, with no reported severe adverse events, with participants showing a high tolerance to the treatment.
  • Based on the exciting Phase 2 results from two studies announced at AD/PD, we believe this could be the first disease-modifying digital therapeutic for the treatment of Alzheimers disease, said Brent Vaughan, CEO, Cognito Therapeutics.

Worldwide Lewy Body Dementia Treatment Industry to 2027 - Featuring Teva Pharmaceuticals, Bayer and Sanofi Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 17, 2021
General Health, Pharmaceutical, Health, Other Health, Branches of biology, Cognitive disorders, Psychiatric diagnosis, Biology, Neuroscience, Dementia, Learning disabilities, Lewy body dementias, Lewy body, Lewy, Alpha-synuclein, Alzheimer's disease

The global Lewy body dementia treatment market size is predicted to reach USD 5.31 billion by 2027.

Key Points: 
  • The global Lewy body dementia treatment market size is predicted to reach USD 5.31 billion by 2027.
  • Lewy body dementia is a progressive disorder associated with dysfunction of the central nervous system and characterized by deposits of alpha-synuclein, a protein in the brain.
  • The unusual deposits in the brain formed Lewy bodies, which can lead to several problems with body movement, thinking, mood, and behavior.
  • Lewy body dementia is the most common disease after Alzheimer's which is rapidly growing and subsequently foster global market growth.

DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders

Retrieved on: 
Wednesday, March 17, 2021
Branches of biology, Biology, Psychiatric diagnosis, University of Bonn, German Center for Neurodegenerative Diseases, Neurodegenerative disorders, Neurodegeneration, Alzheimer's disease, Parkinson's disease, Caghan Kizil

DZNE is a world-leading interdisciplinary public research organization constituted with ten research sites in Germany that investigates methods for prevention, diagnosis and treatment against neurodegenerative diseases.

Key Points: 
  • DZNE is a world-leading interdisciplinary public research organization constituted with ten research sites in Germany that investigates methods for prevention, diagnosis and treatment against neurodegenerative diseases.
  • The collaboration will incorporate DZNE's expertise in the fundamental and clinical research with Eisai's abundant experience in drug discovery for neurodegenerative diseases to accelerate development of novel drug candidates.
  • We think that this collaboration will be able to accelerate creation of new treatments for neurodegenerative disorders, including those for Alzheimer's and Parkinson's.
  • The DZNE investigates all aspects of neurodegenerative diseases in order to develop novel approaches of prevention, treatment, and health care.

MCI Helper e-newsletter to aid Mild Cognitive Impairment patients, says Dr. Leslie Norins, of MCI911.com

Retrieved on: 
Tuesday, March 16, 2021
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Branches of biology, Neuroscience, Mild cognitive impairment, Alzheimer's disease, LinkedIn

New newsletter helps patients cope with Mild Cognitive Impairment, for which no curative drug yet exists.

Key Points: 
  • New newsletter helps patients cope with Mild Cognitive Impairment, for which no curative drug yet exists.
  • The new newsletter will primarily be distributed on request via Facebook and LinkedIn, but is also availablevia free signup .
  • It will also be sent without charge to the thousands already signed up to receive communications from MCI911.com.
  • Its sister group is Alzheimer's Germ Quest, which encourages deeper investigation of the role of microbes in causing Alzheimer's disease.